Which is better, IDXX or PCRX?

On the Buffett-Fit framework, IDEXX Laboratories, Inc. (IDXX) currently grades higher than PCRX — 75/100 (B grade) vs 45/100 (D). That said, "better" depends on which framework you trust — IDXX wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith; PCRX wins on none. The full pillar breakdown is on this page.

Should I buy IDXX or PCRX?

This page is an educational comparison, not investment advice. Both IDXX and PCRX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is IDXX better than PCRX for value investing?

On the Buffett-style value-investing framework, IDXX currently grades higher — 75/100 vs 45/100, a 30-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between IDXX and PCRX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). IDXX currently scores 75/100 (B grade); PCRX scores 45/100 (D grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, IDXX or PCRX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. IDXX and PCRX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, IDXX or PCRX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are IDXX and PCRX both Healthcare stocks?

Yes — both IDEXX Laboratories, Inc. (IDXX) and Pacira BioSciences, Inc. (PCRX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this IDXX vs PCRX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

IDEXX Laboratories

Pacira BioSciences

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

IDXX

IDEXX Laboratories

Market cap

$44.12B

Sector

Healthcare

PCRX

Pacira BioSciences

Market cap

$918.47M

Sector

Healthcare

Overall winner

IDEXX Laboratories IDXX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	IDXX	PCRX	Winner
Warren Buffett	75B	45D	IDXX
Benjamin Graham	80A	55D	IDXX
Philip Fisher	75B	41D	IDXX
Peter Lynch	71B	16F	IDXX
Joel Greenblatt	83C	43D	IDXX
Charlie Munger	87A	41D	IDXX
Terry Smith	84A	41D	IDXX

Side-by-side metrics

Metric	IDXX	PCRX
Market cap	$44.12B	$918.47M
P/E (TTM)	39.0x	181.4x
EV/EBIT	31.6x	35.2x
ROIC (TTM)	40.66%	0.8%
Gross margin	62.05%	79.34%
Net margin	24.63%	0.7%
Revenue CAGR 5y	7.56%	7.62%
EPS CAGR 5y	10.79%	-35.94%
Debt / Equity	0.7x	0.6x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

IDXX leads on

EPS CAGR 5y10.79%vs -35.94%+130%
ROIC (TTM)40.66%vs 0.8%+98%
Market cap$44.12Bvs $918.47M+98%
Net margin24.63%vs 0.7%+97%

PCRX leads on

Gross margin79.34%vs 62.05%+22%
Debt / Equity0.6xvs 0.7x+9%

More like IDXX

IDXX vs 7741.T IDXX vs GMAB IDXX vs LMAT IDXX vs HALO IDXX vs SUNPHARMA.NS IDXX vs MTD

More like PCRX

PCRX vs 7741.T PCRX vs GMAB PCRX vs LMAT PCRX vs HALO PCRX vs SUNPHARMA.NS PCRX vs MTD

Read the full Buffett-Brain analysis for IDXX Read the full Buffett-Brain analysis for PCRX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

IDEXX Laboratories

Pacira BioSciences

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

IDXX

IDEXX Laboratories

Market cap

$44.12B

Sector

Healthcare

PCRX

Pacira BioSciences

Market cap

$918.47M

Sector

Healthcare

Overall winner

IDEXX Laboratories IDXX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	IDXX	PCRX	Winner
Warren Buffett	75B	45D	IDXX
Benjamin Graham	80A	55D	IDXX
Philip Fisher	75B	41D	IDXX
Peter Lynch	71B	16F	IDXX
Joel Greenblatt	83C	43D	IDXX
Charlie Munger	87A	41D	IDXX
Terry Smith	84A	41D	IDXX

Side-by-side metrics

Metric	IDXX	PCRX
Market cap	$44.12B	$918.47M
P/E (TTM)	39.0x	181.4x
EV/EBIT	31.6x	35.2x
ROIC (TTM)	40.66%	0.8%
Gross margin	62.05%	79.34%
Net margin	24.63%	0.7%
Revenue CAGR 5y	7.56%	7.62%
EPS CAGR 5y	10.79%	-35.94%
Debt / Equity	0.7x	0.6x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

IDXX leads on

EPS CAGR 5y10.79%vs -35.94%+130%
ROIC (TTM)40.66%vs 0.8%+98%
Market cap$44.12Bvs $918.47M+98%
Net margin24.63%vs 0.7%+97%

PCRX leads on

Gross margin79.34%vs 62.05%+22%
Debt / Equity0.6xvs 0.7x+9%

More like IDXX

IDXX vs 7741.T IDXX vs GMAB IDXX vs LMAT IDXX vs HALO IDXX vs SUNPHARMA.NS IDXX vs MTD

More like PCRX

PCRX vs 7741.T PCRX vs GMAB PCRX vs LMAT PCRX vs HALO PCRX vs SUNPHARMA.NS PCRX vs MTD

Read the full Buffett-Brain analysis for IDXX Read the full Buffett-Brain analysis for PCRX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.